康臣药业(01681.HK) 公布，国家药品监督管理局于4月28日发布《中药保护品种公告(第25号)(2025年第45号)》，其中载列公司旗下产品“益肾化湿颗粒”已根据《中药品种保护条例》，获批准为中药二级保护品种，全资附属公司广州康臣药业获颁《中药保护品种证书》，该产品将享有7年国家保护期，并可于进一步申请时重续。
康臣药业表示，于保护期内其他企业不得仿制该产品，预料将有利于未来长期发展。(gc/da)(港股报价延迟最少十五分钟。沽空资料截至 2025-04-30 16:25。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.